Clinical Trials Logo

Relapsed Follicular Lymphoma clinical trials

View clinical trials related to Relapsed Follicular Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05848765 Recruiting - Clinical trials for Refractory Follicular Lymphoma

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

REFRACT
Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.

NCT ID: NCT05828589 Recruiting - Clinical trials for Refractory Chronic Lymphocytic Leukemia

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Start date: June 20, 2023
Phase: Phase 1
Study type: Interventional

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum adminstered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Expansion."